Skip to main content Accessibility help

Chloramphenicol Resistance in Vancomycin-Resistant Enterococcal Bacteremia: Impact of Prior Fluoroquinolone Use?

  • Carolyn V. Gould (a1), Neil O. Fishman (a1), Irving Nachamkin (a2) and Ebbing Lautenbach (a1) (a3)



The prevalence of vancomycin-resistant enterococci (VRE) has increased markedly during the past decade. Few data exist regarding the epidemiology of resistance of VRE to chloramphenicol, one of the few therapeutic options.


Survey and case-control study.


A 725-bed, tertiary-care academie medical center and a 344-bed urban community hospital.


Hospitalized patients with blood cultures demonstrating VRE.


We examined the trends in the prevalence of chloramphenicol resistance in VRE blood isolates at our institution from 1991 through 2002 and conducted a case-control study to identify risk factors for chloramphenicol resistance among these isolates.


From 1991 through 2002, the annual prevalence of chloramphenicol-resistant VRE increased from 0% to 12% (P < .001, chi-square test for trend). Twenty-two case-patients with chloramphenicol-resistant VRE bloodstream isolates were compared with 79 randomly selected control-patients with chloramphenicol-susceptible VRE. Independent risk factors for chloramphenicol-resistant VRE were prior chloramphenicol use (odds ratio [OR], 10.9; 95% confidence interval [CI95], 1.72-68.91; P = .01) and prior fluoroquinolone use (OR, 4.74; CI95, 1.15-19.42; P = .03). Chloramphenicol-resistant VRE isolates were more likely to be susceptible to beta-lactams and resistant to tetracycline than were chloramphenicol-susceptible VRE isolates.


Significant increases in the prevalence of chloramphenicol-resistant VRE may limit the future utility of chloramphenicol in the treatment of VRE infections, and close monitoring of susceptibility trends should continue. The association between fluoroquinolone use and chloramphenicol-resistant VRE, reflecting possible co-selection of resistance, suggests that recent dramatic increases in fluoroquinolone use may have broader implications than previously recognized.


Corresponding author

Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 825 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021


Hide All
1.Leclercq, R, Derlot, E, Duval, J, Courvalin, P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157161.
2.Uttley, AHC, Collins, CH, Naidoo, J, George, RC. Vancomycin-resistant enterococci. Lancet 1988;1:5758.
3.Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1997. MMWR 1997;46:16.
4.Murray, BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342:710721.
5.Moellering, RC, Linden, PK, Reinhardt, J, Blumberg, EA, Bompart, F, Talbot, GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemotker 1999;44:251261.
6.Linden, PK, Moellering, RC, Wood, CA, et al.Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001;33:18161823.
7.Gonzales, RD, Schreckenberger, PC, Graham, MB, Kelkar, S, DenBesten, K, Quinn, JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357:1179.
8.Norris, AH, Reilly, JP, Edelstein, PH, Brennan, PJ, Schuster, MG. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995;20:11371144.
9.Lautenbach, E, Schuster, MG, Bilker, WB, Brennan, PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant enterococci. Clin Infect Dis 1998;27:12591265.
10.Ricaurte, JC, Boucher, HW, Turett, GS, Moellering, RC, LaBombardi, VJ, Kislak, JW. Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia. Clin Microbiol Infect 2001;7:1721.
11.Marder, HP, Keyser, FH. Transferable plasmids mediating multiple antibiotic resistance in Streptococcus faecalis subspecies liguifaciens. Antimicrob Agents Chemotker 1977;12:261270.
12.Moellering, RC. Chloramphenicol: an option for vancomycin-resistant enterococci? Journal ofCritical Illness 1996;11:705.
13.Low, DE, Relier, N, Barth, A, Jones, RN. Clinical prevalence, antimicrobial susceptibility, and geographie resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S133S145.
14.Knaus, WA, Drapier, EA, Wagner, DP, Zimmerman, JE. APACHE II: a severity of disease classification System. Crit Care Med 1985;13:818829.
15.Noskin, GA, Peterson, LR, Warren, JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outeome. Clin Infect Dis 1995;20:296301.
16.Facklam, RR, Sahm, DF. Enterococcus. In: Murray, PR, Baron, EJ, Phaler, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology, vol. 6. Washington, DC: American Society for Microbiology; 1995:308314.
17.National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, ed. 5. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000. Approved standard M7-A5.
18.Armitage, P. Test for linear trend in proportions and frequencies. Biometries 1955;11:375386.
19.Kleinbaum, DG, Kupper, LL, Morgenstern, H. Epidemiologic Research: Principles and Quantitative Methods. New York: Van Nostrand Reinhold; 1982.
20.Mantel, N, Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719748.
21.Hosmer, DO, Lemeshow, SL. Applied Logistic Regression. New York: Wiley and Sons; 1989.
22.Greenland, S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989;79:340349.
23.Robins, JM, Greenland, S. The role of model selection in causal inference from nonexperimental data. Am J Epidemiol 1986;123:392402.
24.Prober, CG, Rajchgot, P, Bannatyne, RM, et al.Impact of chloramphenicol use on bacterial resistance in a neonatal intensive care unit. Lancet 1983;2:158.
25.Lautenbach, E, Gould, CV, Larosa, LA, et al.Emergence of resistance to chloramphenicol among vancomycin-resistant enterococcal (VRE) bloodstream isolates. Int J Antimicrob Agents. In press.
26.Lautenbach, E, Fishman, NO, Bilker, WB, et al.Risk factors for fluoro-quinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162:24692477.
27.Alekshun, MN, Levy, SB. Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon. Antimicrob Agents Chemotker 1997;41:20672075.
28.Cohen, SP, McMurry, LM, Hooper, DC, Wolfson, JS, Levy, SB. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemotker 1989;33:13181325.
29.Li, X, Livermore, DM, Nikaido, H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemotker 1994;38:17321741.
30.Lynch, C, Courvalin, P, Nikaido, H. Active efflux of antimicrobial agents in wild-type strains of enterococci. Antimicrob Agents Chemotker 1997;41:869871.
31.Pfaller, MA, Jones, RN, Doern, GV, Sader, HS, Kugler, KC, Beach, ML. Survey of bloodstream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 1999;33:283297.
32.Evans, PA, Norden, CW, Rhoads, S, Deobaldia, J, Silber, JL. In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci. Antimicrob Agents Chemotker 1997;41:1406.
33.Sahm, DF, Marsilio, MK, Piazza, G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the surveillance network database-USA. Clin Infect Dis 1999;29:259263.
34.Lautenbach, E, Bilker, WB, Brennan, PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Contrat Hosp Epidemiol 1999;20:318323.
35.Neuhauser, MM, Weistein, RA, Rydman, R, Danziger, LH, Karam, G, Quinn, JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885888.

Related content

Powered by UNSILO

Chloramphenicol Resistance in Vancomycin-Resistant Enterococcal Bacteremia: Impact of Prior Fluoroquinolone Use?

  • Carolyn V. Gould (a1), Neil O. Fishman (a1), Irving Nachamkin (a2) and Ebbing Lautenbach (a1) (a3)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.